HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on PDS Biotechnology (NASDAQ:PDSB) with a maintained price target of $21.
March 27, 2024 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on PDS Biotechnology with a $21 price target.
The reiteration of a Buy rating and a significant price target of $21 by HC Wainwright & Co. suggests a strong bullish outlook for PDS Biotechnology. This endorsement by a reputable analyst could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100